Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

AIMS: Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium‐free, non‐absorbed potassium binder approved for HK treatment. We retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitt, Bertram, Bakris, George L., Weir, Matthew R., Freeman, Mason W., Lainscak, Mitja, Mayo, Martha R., Garza, Dahlia, Zawadzki, Rezi, Berman, Lance, Bushinsky, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073017/
https://www.ncbi.nlm.nih.gov/pubmed/29767459
http://dx.doi.org/10.1002/ehf2.12292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073017/
https://www.ncbi.nlm.nih.gov/pubmed/29767459
http://dx.doi.org/10.1002/ehf2.12292

Ejemplares similares